Implantable insulin delivery pumps

References

• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long- term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. Implementation of treatment proto- cols in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:361–76.
   Google Scholar
• Selam JL, Charles MA. Devices for insulin administra- tion. Diabetes Care 1990;13:955–79.
   PubMed Web of Science ®Google Scholar
• Zinman B. The physiologic replacement of insulin. An elusive goal. N Engl J Med 1989;321:363–70.
   PubMed Web of Science ®Google Scholar
• Zinman B, Tildesley H, Chiasson JL, Tsui E, et al. Insulin lispro in CSII: results of double-blind crossover study. Diabetes 1997;46:440–3.
   PubMed Web of Science ®Google Scholar
• Melki V, Renard E, Lassmann-Vague V, Boivin S, et al. Improvement of HbA1c and blood glucose stability in IDDMpatients treated with lispro insulin analog in external pumps. Diabetes Care 1998;21:977–82.
   PubMed Web of Science ®Google Scholar
• Blackshear PJ, Shulman GI, Roussell AM, Nathan DM, et al. Metabolic response to three years of continuous, basal rate intravenous insulin infusion in type II diabetic patients. J Clin Endocrinol Metab 1985;61:753–60.
   Google Scholar
• Albisser AM, Leibel BS, Ewart TF, Davidovac Z, et al. Clinical control of diabetes by the artifcial pancreas. Diabetes 1974;23:297–404.
   Google Scholar
• Diagnostic and therapeutic technology assessment. Continuous peritoneal insulin infusion and implantable insulin infusion pumps for diabetic control. JAMA 1989; 262:3195–8.
   Google Scholar
• Schade DS, Eaton RP, Davis T, Akiya F, et al. The kinetics of peritoneal insulin absorption. Metabolism 1981;30:149–55.
   PubMed Web of Science ®Google Scholar
• Nelson JA, Stephen R, Landau ST, Wilson DE, et al. Intraperitoneal insulin administration produces a positive portal-systemic blood insulin gradient in unanesthetized, unrestrained swine. Metabolism 1982;31:969–72.
   Google Scholar
• Selam JL, Raymond M, Jacquemin JL, Orsetti A, et al. Pharmacokinetics of insulin infused intra-peritoneally via portable pumps. Diabete Metab 1985;11:170–3.
   Google Scholar
• Giacca A, Caumo A, Galimberti G, Petrella G, et al. Peritoneal and subcutaneous absorption of insulin in type 1 diabetic subjects. J Clin Endocrinol Metab 1993; 77:738–42.
   Google Scholar
• Irsigler K, Kritz H. Alternate routes of insulin delivery. Diabetes Care 1980;3:219–28.
   Google Scholar
• Selam JL, Slingeneyer A, Hedon B, Mares P, et al. Long-term ambulatory peritoneal insulin infusion of brittle diabetes with portable pumps: comparison with intravenous and subcutaneous routes. Diabetes Care 1983;6:105–11.
   PubMedGoogle Scholar
• Selam JL, Slingeneyer A, Saeidi S, Mirouze J. Experi- ence with long-term peritoneal insulin infusion with portable pumps. Diabetic Med 1985;2:41–4.
   Google Scholar
• Point Study Group. One-year trial of a remote- controlled implantable insulin infusion system in type I diabetic patients. Lancet 1988;i:864–9.
   Google Scholar
• Grau U, Saudek CD. Stable insulin preparation for implanted insulin pumps. Laboratory and animal trials. Diabetes 1987;36:1453–9.
   PubMed Web of Science ®Google Scholar
• Saudek CD, Selam JL, Pitt HA, Waxman K, et al. A, preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med 1989;321:574–9.
   PubMed Web of Science ®Google Scholar
• Selam JL, Micossi P, Dunn FL, Nathan DM. Clinical trial of programmable implantable insulin pumps for type 1 diabetes. Diabetes Care 1992;15:877–85.
   PubMed Web of Science ®Google Scholar
• Selam JL, Raccah D, Jeandidier N, Lozano JL, et al. Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumlps versus intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care 1992;15:53–8.
   PubMed Web of Science ®Google Scholar
• Renard E, Lauton D, Bonifacj C, Costalat G, et al. Experience with intraperitoneal insulin infusion from implantable programmable systems in type 1 (insulin- dependent) diabetes mellitus previously treated by external pumps. Diabete Metab 1993;19:364–71.
   Google Scholar
• Udelsman R, Chen H, Loman K, Pitt HA, et al. Implanted programmable insulin pumps: one hundred ffty-three patient years of surgical experience. Surgery 1997;122:1005–11.
   Google Scholar
• Broussolle C, Jeandidier N, Hanaire-Broutin H, for The Evadiac Study Group. French multicentre experience with implantable insulin pumps. Lancet 1994; 343: 514–5.
   PubMed Web of Science ®Google Scholar
• Hanaire-Broutin H, Broussolle C, Jeandidier N, Renard E, et al. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM: A multi- center study. Diabetes Care 1995;18:388–92.
   PubMed Web of Science ®Google Scholar
• Saudek CD, Duckworth WC, Giobbie-Hurder A, Hen- derson WG, et al. Implantable insulin pumps vs. multiple dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. JAMA 1996;276:1322–7.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Dunn FL, Bruch J, McKitrick C, et al. Postprandial insulin profles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients. Am J Med 1996;100:412–7.
   Google Scholar
• Oskarsson PR, Lins PE, Backman L, Adamson UC. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycemia in type 1 diabetic patients. Diabetes Metab 2000; 26: 118–24.
   PubMed Web of Science ®Google Scholar
• Oskarsson PR, Lins PE, Wallberg-Henriksson H, Adamson UC. Metabolic and hormonal responses to exercise in type 1 diabetic patients during continuous subcutaneous, as compared to continuous intraperi- toneal, insulin infusion. Diabetes Metab 1999;25:491–7.
   Google Scholar
• Renard E, Bringer J, Jacques-Apostol D, Lauton D, et al. Complications of the pump-pocket may represent a signifcant cause of incidents with implanted systems for intraperitoneal insulin delivery. Diabetes Care 1994; 17:1064–6.
   PubMed Web of Science ®Google Scholar
• Scavini M, Cristallo M, Sarmiento M, Dunn FL. The Infusaid Multicenter Implantable Insulin Pump Study Group. Pump-pocket complications during long-term insulin delivery using an implanted programmable pump. Diabetes Care 1996;19:384–5.
   PubMed Web of Science ®Google Scholar
• Belicar P, Lassmann-Vague V, The EVADIAC Study Group. Local adverse events associated with long- term treatment by implantable insulin pumps. Diabetes Care 1998;21:325–6.
   Google Scholar
• Renard E, Rostane T, Carriere C, Marchandin H, et al. Implantable insulin pumps: infections most likely due to seeding from skin fora determine severe outcomes of pump-pocket seromas. Diabetes Metab 2001;27:62–5.
   Google Scholar
• Scavini M, Galli L, Reich S, Eaton RP, et al. The Implantable Insulin Pump Trial Study. Catheter survival during long-term insulin therapy with an implanted programmable pump. Diabetes Care 1997;20:610–3.
   PubMed Web of Science ®Google Scholar
• Renard E, Baldet P, Picot MC, Jacques-Apostol D, et al. Catheter complications with implantable systems for peritoneal insulin delivery. An analysis of frequency, predisposing factors and obstructing materials. Dia- betes Care 1995;18:300–6.
   PubMed Web of Science ®Google Scholar
• Renard E, Bouteleau S, Jacques-Apostol D, Lauton D, et al. Insulin underdelivery from implanted pumps using peritoneal route: determinant role of insulin- pump compatibility. Diabetes Care 1996;19:812–7.
   PubMed Web of Science ®Google Scholar
• Kessler L, Tritschler S, Bohbot A, Sigrist S, et al. Macrophage activation in type 1 diabetic patients with catheter obstruction during peritoneal insulin delivery with an implantable pump. Diabetes Care 2001; 24: 302–7.
   PubMed Web of Science ®Google Scholar
• Renard E, Raingeard I, Costalat G, Apostol D, et al. Aseptic peritonitis revealed through recurrent catheter obstructions in type 1 diabetic patients treated with continuous peritoneal insulin infusion. Diabetes Care 2004;27:276–7.
   Google Scholar
• Renard E, Souche C, Jacques-Apostol D, Lauton D, et al. Improved stability of insulin delivery from implanted pumps using a new preparation process for infused insulin. Diabetes Care 1999;22:1371–2.
   Google Scholar
• Gin H, Renard E, Melki V, Boivin S, et al. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab 2003;29:602–7.
   PubMed Web of Science ®Google Scholar
• Olsen CL, Chan E, Turner DS, Iravani M, et al. Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems. Diabetes Care 1994; 17: 169–76.
   PubMed Web of Science ®Google Scholar
• Jeandidier N, Boivin S, Sapin R, Rosart-Ortega F, et al. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia 1995;38:577–84.
   PubMed Web of Science ®Google Scholar
• Lassmann-Vague V, Belicar P, Raccah D, Vialettes B, et al. Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps. Diabetes Care 1995;18:498–503.
   Google Scholar
• Catargi B, Meyer L, Melki V, Renard E, et al., for the EVADIAC Study Group. Comparison of blood glucose stability and HbA1c between implantable insulin pumps using U400 HOE 21Ph insulin and external pumps using lispro in type 1 diabetic patients: a pilot study. Diabetes Metab 2002;28:133–7.
   Google Scholar
• De Vries JH, Eskes SA, Snoek FJ, Pouwer F, et al. Continuous intraperitoneal insulin infusion in patients with ‘brittle’ diabetes: favourable effects on glycaemic control and hospital stay. Diabet Med 2002; 19: 496–501.
   Google Scholar
• Lassmann-Vague V, Guerci B, Hanaire-Broutin H, Pinget M, et al. Utilisation des pompes a’ insuline implantables: la position d’EVADIAC. Diabetes Metab 1997;23:242–50.
   Google Scholar
• Jaremko J, Rorstad O. Advances toward the implan- table artifcial pancreas for treatment of diabetes. Diabetes Care 1998;21:444–50.
   PubMed Web of Science ®Google Scholar
• Renard E. Implantable closed loop glucose-sensing and insulin delivery: the future for insulin pump therapy. Curr Opin Pharmacol 2002;2:708–16.
   PubMed Web of Science ®Google Scholar